ASC37Beyond's analysis on ASC372026-07-27 — Ascletis' once-monthly GLP-1/GIP/GCGR triple agonist ASC37 shows 88% superior weight loss vs tirzepatide in obese mice, signaling a potential next‑generation obesity therapyRecent news mentioning ASC372026-07-27 — Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse ModelBrowse the full archive →